Airway Therapeutics
Manufacturing · Georgia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1200 Johnson Ferry Rd Ste 300, Marietta,...Phone Number
(513) 770-9630Website
www.airwaytherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Airway Therapeutics
Airway Therapeutics is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, beginning with the most vulnerable populations. The company is advancing the novel recombinant human protein hSP-D, a version of an endogenous protein that reduces inflammation and infection in the body while modulating the immune response. AT-100 is Airway's first candidate in development for prevention of BPD in very preterm infants and for treatment of COVID-19 in seriously ill mechanically ventilated patients.Explore more
Airway Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Airway Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Airway Therapeutics
Product Launch: Get notified when Airway Therapeutics launches new products
Earning: See what the market has to say on Airway Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Airway Therapeutics is spiking on competitors!
Airway Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Airway Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Airway Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Airway Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Airway Therapeutics
Find 2 more new buyers
Compare Similar Companies to Airway Therapeutics
Compare insights from companies similar to Airway Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Airway Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Airway Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Airway Therapeutics.
Airway Therapeutics financials insights
Gather financial insights about Airway Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$4.6M
2017
Debt
$6.3M
2018
Series B
$11M
2020
Series C
$15.5M
Debt
$150K
Airway Therapeutics Tech Stack
A closer look at the technologies used by Airway Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Person-Based
Marc Salzberg, Chairman, Chief Executive Officer and Medical Officer, appeared on a podcast called "The Bio Report" on 10/01/2025. Topics discussed include Preterm infants, lung disease, biologics.
Events, Podcast
Funding
Airway Therapeutics has received an SBA PPP loan for $150,000-350,000 from JPMorgan Chase Bank.
Funding
Funding
Airway Therapeutics News & Media
Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpultide Alfa for Preterm Neonates at Risk of Bronchopulmonary Dysplasia
ATLANTA--(BUSINESS WIRE)--Zelpultide alfa would be the first preventive therapy to protect babies from BPD, which is a debilitating lung disease.Airway Therapeutics Wins 2024 ATS Whitsett Award for Abstract of Positive Phase 1b Results of Zelpultide Alfa in Preterm Neonates at Risk of Bronchopulmonary Dysplasia
ATLANTA--(BUSINESS WIRE)--Airway to begin multicenter pivotal trial in Spain and Italy to evaluate efficacy of zelpultide alfa in preventing BPD compared to standard of care.Visgenx Appoints William Pedranti as Chief Executive Officer - Medtech Alert
Visgenx, a biotech developing gene therapies for retinal diseases, announced the appointment of William Pedranti as Chief Executive Officer.Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia
ATLANTA--(BUSINESS WIRE)--Airway Therapeutics Completes Enrollment in 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Airway Therapeutics
Sign Up For FreeTo access detailed company insights
Airway Therapeutics is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, beginning with the most vulnerable populations. The company is advancing the novel recombinant human protein hSP-D, a version of an endogenous protein that redu... Read More
